Back to search results

Natural History Study of Synucleinopathies

This is an observational study looking at synucleinopathies, a group of rare diseases like Parkinson's disease, that involve the buildup of a protein called alpha-synuclein in the brain. Researchers want to create a detailed database of primary autonomic disorders (problems with body functions like blood pressure control) related to these conditions. This study is open to both men and women aged 18 and older who experience dizziness or lightheadedness when standing up, which improves when lying down. The study aims to track these conditions over five years to better understand how they progress. The current status of this study is unclear.

Study design
This is an observational study with a planned enrollment of 800 participants. It is not a treatment study but rather focuses on understanding the natural course of synucleinopathies.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for five years to create a database of primary autonomic disorders.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01799915

Natural History Study of Synucleinopathies

Recruiting
Not specifiedAges 18+Observational
NYU Langone Health
~800 participants
Updated 2026-06-10 on ClinicalTrials.gov

At a glance

Recruiting sites
8 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To create a database of primary autonomic disorders that will serve as a phenotyping core.
Measured over 5 years

Conditions

Patients With Synucleinopathies
Neurogenic Orthostatic Hypotension
Pure Autonomic Failure
REM Sleep Behavior Disorder
Parkinson Disease
Dementia With Lewy Bodies
Multiple System Atrophy
Shy-Drager Disease

Explore related trials

Lewy Body DementiaMultiple System AtrophyNeurogenic Orthostatic HypotensionParkinson DiseasePure autonomic failureREM sleep behavior disorderSynucleinopathy

NCT01799915

Where you'd take part

This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusettsstudy coordinator listed

    Recruiting

  • BioCruces Research Institute - Hospital Universitario de Cruces

    Bilbao, Spainstudy coordinator listed

    Recruiting

  • FLENI - Fundación para la Lucha contras las Enfermedades Neurológicas

    Buenos Aires, Argentinastudy coordinator listed

    Recruiting

  • Mayo Clinic

    Rochester, Minnesotastudy coordinator listed

    Recruiting

  • NYU Medical Center

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Seoul National University Hospital

    Seoul, South Koreastudy coordinator listed

    Recruiting

  • University of Michigan

    Ann Arbor, Michiganstudy coordinator listed

    Recruiting

  • Vanderbilt Univeristy

    Nashville, Tennesseestudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Horacio C Kaufmann, MD · PRINCIPAL_INVESTIGATOR · NYU MEDICAL CENTER

Who to contact

Horacio Kaufmann, MD
[email protected]
212-263-7225
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • To create a database of primary autonomic disorders that will serve as a phenotyping core.5 years

    We will create an enrollment database of patients with primary autonomic disorders. All patients will have standardized phenotyping evaluations that will combine clinical, physiological and biochemical strategies to characterize complex autonomic phenotypes, both known and still undiscovered.